TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25573527
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus dexamethasone (12 mg/m2 on days 1-4 of a 28-day cycle)
Study: 21294770
Drug: Sensor-augmented insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensor-augmented insulin pump therapy (n = 44)
Study: 21294770
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (n = 39)
Study: 19817242
Drug: G-glove
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G-glove
Study: 18841284
Drug: Clopidogrel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel treatment (75 mg/d)
Study: 8513522
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml bupivacaine, 0.125% in normal saline followed by the same amount of bupivacaine dissolved in 50% glycerin
Study: 8513522
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml bupivacaine, 0.125% in 50% glycerin followed by the same amount of bupivacaine in normal saline
Study: 3104371
Drug: Therapist-assisted relaxation
Normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapist-assisted relaxation treatment
Study: 3104371
Drug: Self-help relaxation
Normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help relaxation treatment
Study: 31430297
Drug: ASO3B adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASO3B adjuvanted split virion vaccine
Study: 31430297
Drug: Whole virion
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole virion non‐adjuvanted vaccine
Study: 23018281
Drug: Amisulpride 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 800 mg/day (AMI-800 group)
Study: 23018281
Drug: Amisulpride 400
Normalized name: amisulpride 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 400 mg/day (AMI-400 group)
Study: 23023308
Drug: Esmolol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1.5 mg/kg iv 90 seconds before intubation
Study: 23023308
Drug: Esmolol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1.5 mg/kg iv 3 minutes before intubation
Study: 23023308
Drug: Esmolol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1.5 mg/kg iv 6 minutes before intubation
Study: 17646693
Drug: Upper WBC
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper WBC quartiles (7.3-8.8; >=8.9 x 10(9)/l)
Study: 15710939
Drug: HIV-1 vaccine
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 vaccine trial participants
Study: 15710939
Drug: Participants believing
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants believing they received the vaccine
Study: 15710939
Drug: Participants believing
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants believing vaccine efficacy was greater than 50%
Study: 15710939
Drug: Participants believing
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants believing they received the vaccine and that vaccine efficacy was greater than 50%
Study: 12189543
Drug: Epirubicin 20
Normalized name: epiRUBicin 200 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 20 mg m(‐2) for 3 weeks followed by 1 week of rest (1 cycle) and gemcitabine 1000 mg m(‐2) after Epirubicin on the same day
Study: 12189543
Drug: Epirubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin and gemcitabine combination therapy
Study: 10071291
Drug: Chemotherapy (tamoxifen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (tamoxifen, cisplatin, and dacarbazine)
Study: 10071291
Drug: Chemoimmunotherapy (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy (chemotherapy followed by interferon alfa-2b and interleukin-2)
Study: 7585854
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TAA) Aqueous nasal spray (220 micrograms once daily)
Study: 2188493
Drug: Controlled-release isosorbide-5-mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release isosorbide-5-mononitrate 60 mg once daily
Study: 2188493
Drug: Conventional isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional isosorbide dinitrate 20 mg 3 times daily
Study: 31187937
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with 10% 5-aminolevulinic acid (ALA)
Study: 31187937
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with 5% 5-aminolevulinic acid (ALA)
Study: 28836954
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group 2 (IG2; n = 169) - therapists provided with feedback and clinical support tools, along with personalized treatment recommendations.
Study: 24144472
Drug: F4/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: F4/AS01 vaccine
Study: 11421876
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate with amoxicillin and clarithromycin (RAC)
Study: 11421876
Drug: Omeprazole with
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole with amoxicillin and clarithromycin (OAC)
Study: 7948453
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication after 4 weeks
Study: 7948453
Drug: Higher blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher blood levels of antipsychotic medication
Study: 3129114
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with cimetidine 400 mg at bedtime
Study: 3129114
Drug: Intermittent 'healing'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent 'healing' doses of cimetidine for 4 to 8 weeks
Study: 21767934
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting injection risperidone (RLAI)
Study: 21767934
Drug: Oral risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral risperidone (RisO)
Study: 11101480
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation with oral rehydration therapy
Study: 1612357
Drug: Sodium butyrate
Normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium butyrate (100 mmol/L)
Study: 6734925
Drug: Difflam Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difflam Oral Rinse (benzydamine hydrochloride 0.15% w/v)
Study: 6734925
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin (acetyl salicylic acid)
Study: 30953536
Drug: Short-term mentalization-based
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term mentalization-based therapy (20 weeks)
Study: 30953536
Drug: Long-term mentalization-based
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term mentalization-based therapy (14 months)
Study: 26461858
Drug: Intervention (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (10 weekly educational sessions led by promotoras)
Study: 23788755
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival (OS) from start of induction chemotherapy
Study: 11815493
Drug: Culturally competent
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally competent diabetes self-management education intervention over 12 months, consisting of 52 contact hours, including 3 months of weekly sessions and 6 months of biweekly support group sessions.
Study: 10414041
Drug: Quinine (750-850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (750-850 mg for 24 hours over 4.1 +/- 1.7 days)
Study: 2027071
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg to start and 100 mg per day for 3 weeks)
Study: 7250175
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN) 30 mg
Study: 7250175
Drug: Sustained released
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained released ISDN 20 mg
Study: 7250175
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN) 20-30 mg
Study: 7250175
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN) 5 mg
Study: 7250175
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN) 10 to 50 mg
Study: 29053202
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 (20 μg/day)
Study: 29053202
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 (40 μg/day)
Study: 29053202
Drug: Ex-BID (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex-BID (10 μg BID)
Study: 29053202
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 (after 3-fold dose escalation)
Study: 27956826
Drug: Trimebutine 200
Normalized name: trimebutine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine 200 mg three times daily half an hour before meals
Study: 27956826
Drug: Probiotics (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (60 mg per-tablet of Lactobacillus acidophilus and Bifidobacterium infantis), 2×/d, 1 hour after meals
Study: 23602614
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice (500 mL daily)
Study: 23602614
Drug: Hesperidin (292
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hesperidin (292 mg in a capsule with isocaloric control beverage)
Study: 22076245
Drug: Ecstasy (MDMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecstasy (MDMA 100 mg) and Alcohol (BAC 0.5‰)
Study: 1873888
Drug: Albendazole 8-10
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 8-10 mg/kg.d, 2-3 times a day for 30 days, followed by a 10-day break, continued for 3-12 months (Group I, 72 cases)
Study: 1873888
Drug: Albendazole 15.6-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 15.6-20 mg/kg.d for 14 days, every two weeks with a 10-day interval for 3-6 months (Group II, 8 cases)
Study: 6224046
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg MPA p.o. daily
Study: 6224046
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg MPA i.m. on 5 days per week
Study: 6224046
Drug: Hormone profile
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone profile monitoring (cortisol and prolactin)
Study: 26942907
Drug: Deprescribing intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deprescribing intervention (n = 47) - planned cessation of non-beneficial medicines
Study: 20635179
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of alcohol (0.8 g/kg)
Study: 20635179
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of alcohol (0.4 g/kg)
Study: 12195763
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg for 3 days, then 50 mg for 4 days (15 mg and 30 mg for patients over 65 years)
Study: 7986242
Drug: Commercial tablet
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial tablet
Study: 3141891
Drug: GHRH administered
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH administered subcutaneously every 3 hours (n = 10)
Study: 3141891
Drug: GHRH administered
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH administered subcutaneously every 3 hours overnight only (n = 10)
Study: 3141891
Drug: GHRH administered
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH administered by twice daily injections (n = 4)
Study: 3141891
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment with GHRH (n = 16)
Study: 3141891
Drug: GHRH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH therapy (n = 11 with circulating antibodies)
Study: 5018311
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose as diluent for heparin
Study: 5018311
Drug: 5% sorbitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sorbitol as diluent for heparin
Study: 27720838
Drug: Elbasvir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir (50 mg) and Grazoprevir (100 mg) for 12 weeks
Study: 27720838
Drug: Elbasvir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir (50 mg) and Grazoprevir (100 mg) with Ribavirin for 12 weeks
Study: 27720838
Drug: Elbasvir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir (50 mg) and Grazoprevir (100 mg) for 16 weeks
Study: 27720838
Drug: Elbasvir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir (50 mg) and Grazoprevir (100 mg) with Ribavirin for 16 weeks
Study: 14990402
Drug: 52.5 mg
Normalized name: carbidopa 52.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52.5 mg gel
Study: 14990402
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg gel
Study: 14990402
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg gel
Study: 14990402
Drug: Film (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film (100 mg)
Study: 14990402
Drug: Suppository (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository (100 mg)
Study: 11720694
Drug: Ipsapirone (IPS)
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone (IPS) 0.5 mg/kg, p.o.
Study: 9257201
Drug: Dolasetron mesilate
Normalized name: Dolasetron mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesilate 12.5 mg
Study: 3526900
Drug: Motrin (ibuprofen)
Normalized name: ibuprofen Oral Tablet [Motrin]
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Motrin (ibuprofen)
Study: 24225816
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g·kg‐1BM)
Study: 24225816
Drug: Beta-alanine (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (6.4 g·day‐1 for 4 weeks, 3.2 g·day‐1 for 1 week)
Study: 22807611
Drug: sumatriptan 50
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sumatriptan 50 mg
Study: 17472478
Drug: Eclipta alba
Normalized name: Eclipta prostrata leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eclipta alba (3 g/day in encapsulated form)
Study: 2563465
Drug: 3-monthly tympanometry
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3-monthly tympanometry screening and subsequent treatment for OME
Study: 28196255
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (daily tablets containing 15 µg of major allergen Phleum p 5)
Study: 28196255
Drug: Placebo (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched double-placebo injections)
Study: 28196255
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (monthly injections containing 20 µg of Phleum p 5)
Study: 16926775
Drug: saquinavir-SGC/ritonavir (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: saquinavir-SGC/ritonavir (1600 mg/100 mg)
Study: 15344394
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg once a day
Study: 15344394
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice a day
Study: 10937611
Drug: Fluoxetine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine for 14 weeks followed by placebo for 36 weeks
Study: 10937611
Drug: Fluoxetine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine for 38 weeks followed by placebo for 12 weeks
Study: 10937611
Drug: Fluoxetine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine for 50 weeks
Study: 28639551
Drug: Facet joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facet joint injections (FJIs) with local anaesthetic and corticosteroids (at up to six injection sites) plus best usual care (BUC)
Study: 24908148
Drug: Sublingual Diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Diazepam
Study: 24908148
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment intervention)
Study: 23731674
Drug: Antiandrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiandrogen therapy combined with exercise (AE)
Study: 23731674
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with exercise (CE)
Study: 23731674
Drug: Antiandrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiandrogen therapy without exercise (A)
Study: 23731674
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without exercise (C)
Study: 18258423
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg formoterol fumarate inhalation solution twice daily plus tiotropium (FFIS/TIO)
Study: 18258423
Drug: Nebulized placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized placebo twice daily plus tiotropium (PLA/TIO)
Study: 17069557
Drug: Suspension (hang-back)
Normalized name: Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension (hang-back) recession technique
Study: 10866909
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 12 mL of 0.75% ropivacaine
Study: 10866909
Drug: Multiple injections
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injections of 4 mL of 0.75% ropivacaine at each muscular twitch
Study: 9357393
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg every 24 hours (from day 11 to day 20) with losartan 100 mg every 24 hours
Study: 9357393
Drug: Eprosartan 300
Normalized name: eprosartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 300 mg every 12 hours
Study: 7950612
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (conventional treatment)
Study: 2886560
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg captopril BID
Study: 2886560
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg captopril BID
Study: 2886560
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the dose of captopril (Phase 3)
Study: 2886560
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus diuretic (Phase 4)
Study: 2886560
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (beta blocker-diuretic treatment)
Study: 23380881
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (ACE‐i)
Study: 20826029
Drug: Actovegin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin (30 ml daily, 5 days/week) administered from day 1 of radiotherapy for Group 1 (prevention)
Study: 20826029
Drug: Actovegin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin (30 ml daily, 5 days/week) administered from the onset of grade 2 mucositis for Group 2 (treatment)
Study: 18097226
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment interruption (STI), cycles of 12 weeks on/off (408 participants)
Study: 2859703
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg celiprolol once daily for 3 weeks
Study: 2859703
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg celiprolol in combination with 12.5 mg chlorthalidone for 3 weeks
Study: 2859703
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg celiprolol in combination with 25 mg chlorthalidone for 3 weeks
Study: 2859703
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg celiprolol or in combination with 12.5 mg or 25 mg CT for up to 12 months
Study: 2859703
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 25 mg CT
Study: 29552766
Drug: Endostar combined
Normalized name: Menostar
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endostar combined with cisplatin/pemetrexed chemotherapy
Study: 29552766
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (pemetrexed and cisplatin)
Study: 27314599
Drug: Remifentanil TCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil TCI (effect‐site concentration=1.5 ng.mL‐1)